Paula Payão Ovídio

Paula Payão Ovídio

Auto-generated profile, based on publicly available information

Paula Payão Ovídio

Department of Health Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto 14049-900, SP, Brazil

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
DCDaniela Dalpubel Campanari
Daniela Dalpubel Campanari
UCUalter Guilherme Cipriano
Ualter Guilherme Cipriano
Thais Fernanda de Campos Fraga-SilvaThais Fernanda de Campos Fraga-Silva
Thais Fernanda de Campos Fraga-Silva
LRLeandra Ramalho
Leandra Ramalho
POPaula Payão Ovidio
Paula Payão Ovidio
EFEduardo Ferriolli
Eduardo Ferriolli
Introduction: chronic low-grade inflammation, or inflammaging, emerges as a crucial element in the aging process and is associated with cardiovascular and neurological diseases, sarcopenia, and malnutrition. Evidence suggests that omega-3 fatty acids present a potential therapeutic agent in the prevention and treatment of inflammatory diseases, mitigating oxidative stress, and improving muscle mass, attributes that are particularly relevant in the context of aging. The objective of the present study was to evaluate the effectiveness of supplementation with omega-3 fish oil in improving the immune response and oxidative stress in knockout mice for interleukin IL−10 (IL−10−/−). Material and methods: female C57BL/6 wild-type (WT) and interleukin IL−10 knockout (IL−10−/−) mice were fed during 90 days with a standard diet (control groups), or they were fed/supplemented with 10% of the omega-3 polyunsaturated fatty acid diet (omega-3 groups). Muscle, liver, intestinal, and mesenteric lymph node tissue were collected for analysis. Results: the IL−10−/−+O3 group showed greater weight gain compared to the WT+O3 (p = 0.001) group. The IL−10−/−+O3 group exhibited a higher frequency of regulatory T cells than the IL−10−/− group (p = 0.001). It was found that animals in the IL−10−/−+O3 group had lower levels of steatosis when compared to the IL−10−/− group (p = 0.017). There was even greater vitamin E activity in the WT group compared to the IL−10−/−+O3 group (p = 0.001) and WT+O3 compared to IL−10−/−+O3 (p = 0.002), and when analyzing the marker of oxidative stress, MDA, an increase in lipid peroxidation was found in the IL−10−/−+O3 group when compared to the IL−10−/− group (p = 0.03). Muscle tissue histology showed decreased muscle fibers in the IL−10−/−+O3, IL−10−/−, and WT+O3 groups. Conclusion: the findings show a decrease in inflammation, an increase in oxidative stress markers, and a decrease in antioxidant markers in the IL−10−/−+O3 group, suggesting that supplementation with omega-3 fish oil might be a potential intervention for inflammaging that characterizes the aging process and age-related diseases.

30 October 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
MRMacario Arosti Rebelo
Macario Arosti Rebelo
ACAlessandra Cássia-Barros
Alessandra Cássia-Barros
.C. Conde-Tella
. Conde-Tella
SFSabrina F. Frugeri
Sabrina F. Frugeri
POPaula P. Ovidio
Paula P. Ovidio
Jose Tanus-SantosJose Tanus-Santos
Jose Tanus-Santos
Inorganic nitrite contributes to the nitrosation of biomolecules and exerts antioxidant effects. The proton pump inhibitor omeprazole has pro-oxidant effects, inhibits the formation of nitroso species in the stomach, and abrogates the blood pressure-lowering effects of orally administered nitrite. Here, we examine whether a two-week treatment with nitrite leads to tissue nitrosation that scales with local thiol concentrations and whether oral nitrite treatment can prevent the pro-oxidant effects of omeprazole. Male Sprague–Dawley rats received daily doses of omeprazole 10 mg/kg i.p. (or vehicle) and sodium nitrite 15 mg/kg by gavage (or water) for 14 days. Animals were euthanized 6 h after the last nitrite dose, and blood and tissues (brain, heart, and liver) were collected for biochemical analyses. We found that nitrite treatment increased liver nitrite and total nitroso species (RxNO) concentrations approximately eight-fold (with minor increases in other organs), and omeprazole treatment attenuated these effects. Nitrite treatment selectively elevated non-protein thiol concentrations in the liver, but not in animals also receiving omeprazole. Tissue thiol elevation was associated with increased nitrosation of hepatic proteins, which was prevented by omeprazole. Nitrite upregulated mRNA expression of microsomal glutathione S-transferase-1 (Mgst1) and decreased superoxide and hydrogen peroxide production, especially in rats co-treated with omeprazole. While omeprazole increased liver xanthine oxidoreductase (XOR), nitrite treatment attenuated this effect. These results demonstrate that oral nitrite treatment robustly elevates nitrite and RxNO concentrations in the liver, and these effects are associated with increased hepatic glutathione production and an upregulation of Mgst1 expression, counteracting the pro-oxidant effects induced by omeprazole.

1 March 2024 in Applied Biosciences
Verified
Journal Article
Open access
PDF file
PBPriscila Nogueira Bezan
Priscila Nogueira Bezan
HHHéric Holland
Héric Holland
Bárbara Ferreira VercesiBárbara Ferreira Vercesi
Bárbara Ferreira Vercesi
POPaula Payão Ovídio
Paula Payão Ovídio
LSLivia Maria Cordeiro Simões
Livia Maria Cordeiro Simões
AJAlceu Jordao
Alceu Jordao
Background and objectives: Carbohydrates such as fructooligosaccharides (FOSs) are associated with improved gastrointestinal health and the prevention of excess body fat. We evaluated the long-term effects of high amounts of FOS on metabolic parameters, non-alcoholic fatty liver disease (NAFLD) and short-chain fatty acids (SCFAs). Methods: Sixty C57BL/6 mice received the following diets for four months: control (C), normolipid rich in fiber (F), normolipid supplemented with FOS (FOS), high fat (HL), high fat with high fiber (HLF) and high fat with FOS (HLFOS). We analyzed the animal weight; body composition; food intake; fasting blood glucose; serum and liver lipid profiles; liver and intestinal histologies; malondialdehyde (MDA), hepatic retinol and α-tocopherol; and SCFAs in the feces. Results: Supplementation with FOS in a high-fat diet promoted less body weight gain and reduced liver and retroperitoneal adipose tissue weights compared to HL and HF. FOS prevented NASH and decreased alanine aminotransferase and serum cholesterol levels in experimental animal models of obesity and metabolic syndrome (MS). There were statistical differences found in the dosages of the three main SCFAs in feces (acetic, isobutyric and isovaleric acids). Conclusions: Long-term supplementation with high doses of FOS was effective in reducing weight, adiposity, NAFLD and serum cholesterol in C57BL mice with obesity and MS induced by a high-fat diet.

6 November 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
PBPriscila Nogueira Bezan
Priscila Nogueira Bezan
HHHeric Holland
Heric Holland
BVBárbara Ferreira Vercesi
Bárbara Ferreira Vercesi
POPaula Payão Ovídio
Paula Payão Ovídio
LSLivia Maria Cordeiro Simões
Livia Maria Cordeiro Simões
AJAlceu Jordao
Alceu Jordao
Carbohydrates such as fructooligosaccharides (FOS) are associated with improved gastrointestinal health and prevention of excess body fat. We evaluated the long-term effects of high amounts of FOS on metabolic parameters, non-alcoholic fatty liver disease (NAFLD) and short-chain fatty acids (SCFA). Sixty C57BL/6 mice received diets for four months: control (C), normolipid rich in fiber (F), normolipid supplemented with FOS (FOS), high fat (HL), high fat with high fiber (HLF) and high fat with FOS (HLFOS). We analyzed: animal weight; body composition; food intake; fasting blood glucose; serum and liver lipid profile; liver and intestinal histologies; malondialdehyde (MDA), hepatic retinol and α-tocopherol; SCFA in the feces. Supplementation with FOS in a high-fat diet promoted less body weight gain and reduced liver and retroperitoneal adipose tissue weights compared to HL and HF. FOS prevented NASH and decreased alanine aminotransferase and serum cholesterol levels in experimental animal models of obesity and metabolic syndrome (MS). There was found statistical differences in the dosages of the three main SCFAs in feces (acetic, isobutyric and isovaleric acids). Long-term supplementation with high doses of FOS was effective in reducing weight, adiposity, NAFLD and serum cholesterol in C57BL mice with obesity and MS induced by a high-fat diet.